Study of OT-C001 natural killer cells for large B cell lymphoma
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new treatment made from specially activated natural killer cells from a donor. It is for people with diffuse large B cell lymphoma that has come back or not responded to other treatments, including CAR T-cell therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have diffuse large B cell lymphoma that has returned or not responded to treatment.
- You have no standard treatment options left or cannot get CAR T-cell therapy.
- Your cancer can be measured on scans or tests.
- You are in fairly good health (able to do daily activities without help).
- You do not have other serious medical conditions like uncontrolled infections or heart disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new treatment using immune cells from cord blood, called CAR NK cells, to fight certain types of B-cell lymphoma that have come back or not responded to other treatments. It is designed for people who have tried at least two prior therapies.
This study tests whether adding your own natural killer (nk) cells (a type of immune cell) to your regular treatment helps fight non-hodgkin lymphoma that has come back or not responded. The goal is to see if this extra treatment is safe and works better at stopping the cancer.
This trial tests a new combination of specially grown immune cells (NK cells) plus two drugs that help them attack cancer. It's for people with a type of B-cell lymphoma that came back after at least two prior treatments or a stem cell transplant, and who have either failed or are not eligible for CAR-T cell therapy.
This trial tests a drug called odronextamab for people with large B-cell lymphoma whose cancer did not respond to or came back after initial treatment. The goal is to see if odronextamab can help shrink the tumor before getting CAR-T cell therapy.
This study tests a new cell therapy called CT1190B for people with certain types of B-cell lymphoma that came back or did not improve after other treatments. The therapy uses your own immune cells to fight the cancer, and the study aims to see if it is safe and effective.
This trial tests a new type of cell therapy called CAR NK cells that are designed to find and attack lymphoma cells carrying a marker called CD70. It is for people whose lymphoma either did not go away after the first treatment or came back within a year.
Hear when a new Diffuse Large B-cell Lymphoma With no Other Specification trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.